Skip to main content
CLNN
NASDAQ Life Sciences

Prior Board Member Files Intent to Sell $265K in Clene Inc. Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$4.09
Mkt Cap
$48.173M
52W Low
$2.28
52W High
$13.5
52W Position info
79% above low
Off High info
70% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

CLNN sits 79% above its 52-week low of $2.28.

Summary

Symbiosis II LLC, a prior board member and significant shareholder of Clene Inc., has filed a Form 144 indicating intent to sell common stock valued at approximately $265,731, continuing a pattern of share dispositions.


Key Events · Ownership and Investor Activity · CLNN

  • Proposed Stock Sale

    Symbiosis II LLC has filed a Form 144 indicating intent to sell 60,842 shares of common stock, with an approximate market value of $265,731.

  • Filer's Relationship to Issuer

    The filer, Symbiosis II LLC, is identified as a prior board member and a 10% owner of Clene Inc.

  • Continued Share Distribution

    This proposed sale is part of a larger pattern, as Symbiosis II LLC has already sold 506,384 shares for gross proceeds of over $2.9 million in the past three months, indicating a sustained liquidation of holdings.


Analysis · CLNN · Life Sciences

This Form 144 filing by Symbiosis II LLC, a former board member and 10% owner, signals a continued liquidation of their holdings in Clene Inc. The proposed sale of approximately $265,731 adds to over $2.9 million in shares already sold by this entity in the past three months. This sustained distribution by a significant investor, especially following the company's recent $6.03 million capital raise on January 13, 2026, could be interpreted negatively by the market, suggesting a lack of long-term conviction from a key stakeholder.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CLNN was trading at $4.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $48.2M. The 52-week trading range was $2.28 to $13.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CLNN - Latest Insights

CLNN
Nov 04, 2026, 8:36 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.77
Real-time Price: $3.56 info
Change: -$0.210 (-6%) info
Market Cap: $51.265M info
CLNN
Nov 04, 2026, 8:31 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $3.77
Real-time Price: $3.56 info
Change: -$0.210 (-6%) info
Market Cap: $51.265M info
CLNN
Oct 19, 2026, 8:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $3.16
Real-time Price: $3.56 info
Change: +$0.400 (+13%) info
Market Cap: $51.265M info
CLNN
Sep 16, 2026, 1:05 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $4.09
Real-time Price: $3.56 info
Change: -$0.530 (-13%) info
Market Cap: $51.265M info
CLNN
Sep 15, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.09
Real-time Price: $3.56 info
Change: +$0.470 (+15%) info
Market Cap: $51.265M info